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Introduction
Insulin-dependent diabetes mellitus (IDDM), or type 1 dia-
betes, is a T-cell-mediated autoimmune disease. Much
effort has been devoted over the past two decades to
establishing an immunological treatment that could substi-
tute for insulin therapy. In this chapter, I provide an update
of the noteworthy preclinical data obtained in the sponta-
neous animal models of the disease and of clinical trials in
progress. These data are presented with particular atten-
tion to lessons that could benefit the immunotherapy of
other autoimmune diseases, notably rheumatoid arthritis.
IDDM as an autoimmune disease
It is now firmly established that in the vast majority of
cases, IDDM has an autoimmune origin [1]. This does not
preclude the possible aetiological role of a triggering envi-
ronmental factor, notably a pancreatotropic virus, but the
fact remains that the β-cell lesion is mediated by β-cell-
specific autoreactive T cells.
No consensus has been reached on the nature of the effec-
tor T cell(s). Research on the nonobese diabetic (NOD)
mouse has shown that both CD4 and CD8 clones could
induce the disease separately, but it is likely that the two cell
types cooperate in the β-cell lesion. CD8 T cells could act
through a direct cytotoxic mechanism, although this has not
been proven. CD4 cells could act either as helper T cells or
as effector cells through cytokine production.
Increasing importance is given to various subsets of regu-
latory T cells that have been shown to control the onsets
of diabetes in both the NOD mouse and the BioBreeding
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(BB) rat. Three main types of regulatory T cell have been
described [2]: Th2 cells, which appear after administration
of soluble β-cell autoantigens, CD4+CD25+ T cells, and
natural killer T cells, which probably appear spontaneously
during ontogeny. It is not yet clear whether the onset of
diabetes results from the decline of T-cell-mediated regu-
lation or, what is more likely, from the overriding of the reg-
ulation by activation of β-cell-specific effector T cells.
Another major uncertainty relates to the nature of the
events that trigger such activation. Antigen mimicry or
pancreatic inflammation are the most likely, but not neces-
sarily the only, mechanisms.
Strengths and limitations of the NOD mouse
model
More than 100 reports have been published using the
NOD mouse to set up new immunotherapeutic strategies.
Table 1 presents a nonexhaustive list of the main products
or strategies tested so far.
The large number of successful results in this mouse has
raised the question of the validation of the model as a pre-
clinical tool for identifying strategies to be applied ulti-
mately to humans. For several substances, the success in
the NOD mouse has been confirmed in humans, e.g.
cyclosporin A [3,4], heat shock protein (hsp)60 peptide
[5], and anti-CD3 antibody (K Herold, unpublished obser-
vations). For others, however, such confirmation was not
obtained, e.g. nicotinamide [6], oral insulin [7,8], and BCG
(bacille Calmette–Guérin) [9]. It is important to realise
that, contrary to human diabetes, which is essentially seen
in the clinic when the disease is overt, diabetes in the
NOD mouse can be studied at all stages of its natural
history, including the preclinical stages. It is interesting in
this context that the three drugs shown to be effective in
human diabetes were still efficient in the NOD mouse at
an advanced stage, whereas nicotinamide, BCG, and oral
insulin worked only at the preclinical stage.
An intriguing question is whether the preventive effects
observed after administration of a drug at a very early stage
(e.g. 4–6 weeks of age) are specific. An attractive hypothe-
sis is that early intervention resets the homeostasis of the
immune system before the disease starts to progress irre-
versibly. It could be postulated that there is a checkpoint
before which the disease outcome is not yet fixed. An
agent that would inhibit the triggering event or boost
immunoregulation could then show a long-term effect.
Applied after this checkpoint, the agent would not show
any significant therapeutic effect. To illustrate this concept,
it may be suggested that if a virus causes the initial insult
that triggers the onset of the diabetogenic process and
that virus can be eliminated, an antiviral treatment could be
effective if applied very early but would be ineffective once
the initial inflammation had occurred and induced a sus-
tained immune response to β-cell autoantigens.
The NOD mouse is one of the few spontaneous models of
T-cell-mediated autoimmune diseases, and as such it is of
special interest to all students of autoimmunity. This mouse
strain is also of major interest because it has been used to
generate many genetically modified models in which
various genes have been deleted or overexpressed as
transgenes in various tissues including the β cells (using
the rat insulin promoter). Such mice provide invaluable help
in discerning the mode of action of the various therapeutic
strategies shown to operate in wild NOD mice.
A weakness of the NOD mouse model is that the putative
target β-cell autoantigen(s) is (are) unknown. Several can-
didates have been proposed, such as glutamic acid decar-
boxylase, insulin, hsp60, and IA-2 [1], but no firm evidence
has shown any of them to be primary autoantigens. This is
not necessarily a major pitfall, since data have been accu-
mulated to indicate that such a primary autoantigen may
not exist. Even if it exists, diversification of autoimmune
specificities (antigen spreading) occurs so fast that the
primary antigen may not be crucial. Additionally, at the
level of cytokine-dependent immunoregulation (cytokines
are discussed further in section 6 below), the occurrence
of bystander suppression [10] allows the suppression ini-
tially directed against a given β-cell antigen, whether it is a
primary autoantigen or not, to be extended to most β-cell-
specific T-cell responses.
Preclinical studies: a unique array of
approaches
As mentioned above, a wide spectrum of agents or manip-
ulations has been shown to prevent, and more rarely to
cure, IDDM in NOD mice. They are listed here according
to the factors postulated to contribute to the development
of the disease. The various strategies that have been
reported are presented below, and Table 1 lists the refer-
ence or references relevant to each product or strategy.
1. T-cell depletion or sequestration/diversion
The most straightforward approach to immunotherapy of a
T-cell-mediated autoimmune disease such as IDDM is the
removal of T cells, either targeted as a whole or as
subsets. This has been accomplished in the NOD mouse
using several approaches.
Anti-T-cell depleting antibodies offer the easiest strategy.
One may thus delay the onset of diabetes by administration
of depleting CD4 antibodies such as GK 1.5 and, to a
lesser extent, CD8, CD44, CD45RA, or CD45RB antibod-
ies. However, although the onset of diabetes can be pre-
vented in the best cases, there is no clear effect on overt
disease, even when it is only recently established. In
recently established disease, besides anti-CD3 antibodies,
which essentially act independently of major T-cell depletion
(see below), only a mixture of depleting CD4 and CD8 anti-
bodies or polyclonal antilymphocyte antibodies have beenS5
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Table 1
Immunotherapeutic agents or other treatments used in NOD mice
1 T-cell depletion or sequestration/diversion
1.1 Depletion
Anti-CD3 [28]
Anti-CD4 [40]
Anti-CD8 [41]
Anti-CD44 [42]
Anti-CD45RA [43]
Anti-CD45RB [44]
Anti-Thy l.2 [45]
Antilymphocyte globulin [11,45]
Neonatal thymectomy [46]
1.2 Sequestration/diversion
Anti-CD43 [47]
Anti-VLA-l [48]
Anti-VLA-4 [48,49]
VLA-4/Ig fusion protein [50]
Anti-CD62L [49]
2 Blockade of T-cell activation
2.1 Chemical immunosuppressants
Cyclosporin A [51]
FK-506 [52]
Azathioprine [53]
Rapamycin [54]
Deoxyspergualin [55]
2.2 γ Irradiation [56]
3 Targeting of T-cell receptors
3.1 TCRαβ antibody [13]
3.2 CD3 antibody [28]
3.3 Vβ8 antibody [57]
3.4 T-cell vaccination
Polyclonal activated T cells [58]
Glutaraldehyde-treated T cells [59]
Activated T cells
Vβ8 T cells [60]
Anti-hsp60 T-cell clone [61]
3.5 Blocking peptides [62]
4 Targeting of MHC molecules
4.1 Anti-class-I [63]
4.2 Anti-class-II [64]
4.3 MHC transgenic mice
Class I [65]
I-A [16,66]
I-E [67]
5 Targeting of costimulation and adhesion molecules
5.1 Costimulation molecules
Anti-CD28 [68]
CTLA-4–Ig fusion protein [69]
Anti-B7.2 [69]
Anti-CD40L [70]
5.2 Adhesion molecules
Anti-ICAM-1 [71]
Soluble ICAM-1
Recombinant protein [72]
Gene therapy (P Lemarchand, unpublished observations)
Anti-Mac [73]
Anti-LFA-l [71]
6 Cytokine blockade
6.1 IFN-γ
Anti-IFN-γ [74,75]
IFN-γR/IgG1 fusion protein [76]
6.2 IL-2
Anti-IL-2R [77]
IL-2R/Ig fusion protein [78]
IL-2 diphtheria-toxin protein [79]
6.3 IL-12
Anti-IL-12 [80]
IL-12 antagonist (p40)2 [81]
6.4 IFN-α (oral) [82]
6.5 IL-1
IL-1 antibody [83]
IL-1 antagonist [84]
6.6 IL-6 [75]
6.7 Lymphotoxin receptor [85]
7 Pharmacologically active cytokines
7.1 IL-4 [86]
7.2 IL-10 [87,88]
7.3 IL-13 [89]
7.4 IL-3 [37]
7.5 G-CSF (F Zavala, unpublished observations)
7.6 Lymphotoxin [90]
7.7 IL-11 [91]
7.8 IL-1α [92]
7.9 TNF-α [26]
8 Tolerance to soluble β-cell autoantigens
8.1 Insulin
Oral [93]
Oral + IL-10 [94]
Intranasal [34,95]
Subcutaneous
Native protein [96]
B chain [96]
Inactive analogue [95,97]
DNA vaccination [98]
Gene-transfer delivery [99] (proinsulin gene)
Cholera-toxin conjugate [100]
8.2 Glutamic acid decarboxylase (GAD)
Oral [101]
Intranasal [102]
Subcutaneous [103]
Intrathymic [104]
DNA vaccination [105]
Anti-GAD antibody [106]
8.3 Heat shock protein 60 (hsp60)
Subcutaneous or intraperitoneal
Protein [107]
P277 peptide [108,109]
Gene-transfer delivery [110]
8.4 Pancreatic extracts (oral) [111]
9 Stimulation of regulatory T cells
9.1 Pathogens
Bacteria
Mycobacteria
Mycobacterium bovis [112]
M. avium [113]
Complete Freund’s adjuvant [114]
Lactobacillus casei [115]
Streptococcal extract [116]
Klebsiella extract [117]
Escherichia coli (+ oral insulin) [118]
Viruses
Mouse hepatitis virus [119]
Lactate dehydrogenase virus [120]
Lymphocytic choriomeningitis virus [121]
Parasites
Filariae [122]
Schistosomes [123]
9.2 Stimulation of innate immunity
α-Galactosylceramide [33,124]
Continued overleafS6
found to reverse the disease [11]. Immunosuppression is
not specific to β-cell antigens and may be prolonged, thus
exposing the patient to the hazards of generalised immuno-
suppression. A more subtle approach, which is probably
less hazardous but also less efficient, targets T-cell homing
molecules, aiming at diverting pathogenic T cells or their
precursors from migrating to the islets. This is the putative
mode of action of anti-VLA-1, anti-VLA-4, anti-CD43, and
anti-L-selectin (CD62L) antibodies.
2. Blockade of T-cell activation
A less radical but similar approach to the previous one is
to reversibly block T-cell activation. At present, this is
achieved using chemical immunosuppressants.
Most drugs used in organ transplantation where T cells
are also incriminated have been used, and these include,
notably, cyclosporin A, azathioprine, rapamycin, FK506,
and deoxyspergualin. Again, these drugs essentially
worked when given early in the course of the disease as a
preventive, but not a curative, treatment. This point is illus-
trated by results reported by Wang and Lafferty and their
coworkers, showing that in diabetic NOD mice trans-
planted with syngeneic islets, recurrence of diabetes
could be prevented by a depleting CD4 antibody (GK 1.5)
but not by cyclosporin A [12].
3. Targeting of T-cell receptors
T-cell-receptor(TCR)-mediated recognition of β-cell
autoantigens is a central step in the diabetes pathogene-
sis, at both the triggering and the effector phases. It was
thus logical to attempt to block TCRs. This has been suc-
cessfully achieved using a number of approaches.
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Table 1 continued
Immunotherapeutic agents or other treatments used in NOD mice
9.3 Nondepleting anti-T-cell antibodies
Anti-CD3 [28]
Anti-CD4 [30]
Superantigens [125]
10 Gene therapy
10.1 β-cell antigens
DNA vaccination [98,105]
GAD immunoglobulin [126]
10.2 IL-4
Retrovirus (T-cell transfection) [127]
Biolistic [128]
Adenovirus [129]
IL-4/IgG1 fusion protein [130]
10.3 IL-10
T-cell transfection [131]
Local [132]
Systemic [133]
10.4 ICAM-1 (P Lemarchand, in preparation)
10.5 IFN-γR/IgGl fusion protein [76,130]
10.6 TGF-β [134]
10.7 Calcitonin [135]
11 Cell therapy
11.1 Islet or segmental pancreas transplantation 
(+ immunosuppression)
Syngeneic [12]
Allogeneic [136] (+ immunosuppression)
11.2 Intrathymic islet transplantation [38]
11.3 Bone marrow transplantation
Allogeneic [137,138]
Syngeneic [37]
11.4 Dendritic cells [139,140]
11.5 Natural killer T cells [141]
11.6 CD4 cell lines
Polyclonal [142]
Anti-Iag7 [143]
11.7 Allogeneic cells
Macrophages [144]
Spleen cells [36]
12 Inhibition of β-cell lesion
12.1 Nicotinamide [145]
12.2 Antioxidants
Vitamin E [146]
Probucol analog [147]
Probucol + deflazacort [148]
Aminoguanidine [149]
12.3 Anti-inflammatory agents
Pentoxifylline [150]
Rolipram [150]
13 Miscellaneous
13.1 Immunomodulators
Linomide [151]
Ling-zhi-8 [152]
D-Glucan [153]
Multi-functional protein 14 [154]
Ciamexon [155]
Cholera toxin B [156,157]
Vanadate [158]
Vitamin D3 analogue [159]
13.2 Hormones and related proteins
Androgens [160]
IGF-I [153]
13.3 Immunomanipulation
Natural antibodies [161,162]
Lupus idiotype [163]
Lipopolysaccharide [164,165]
13.4 Diet
Casein hydrolysate [166,167]
13.5 Other
Sulfatide [168]
Bee venom [90]
Kampo formulation [169]
Silica [170]
Ganglioside [171]
Antiasialo GM-1 antibody [172]
Hyaluronidase [42]
Concanavalin A [173]
CD45RA(B), CD45 receptor A(B); CDXXL, CDXX ligand; CFA, complete Freund’s adjuvant; GAD, glutamic acid decarboxylase; G-CSF,
granulocyte-colony-stimulating factor; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; MHC, major histocompatibility complex; TCR,
T-cell receptor; V, variable region (of immunoglobulin); VLA, very late antigen.S7
Global TCR blockade can be obtained by administering
antibodies directed against the constant portion of αβ
TCRs or to the CD3 complex with which TCR is tightly
associated both physically and functionally. In the case of
CD3, though, the blockade effect is only part of the anti-
body mode of action, which also involves depletion (at
least when the entire antibody molecule is used) and
especially T-cell activation notably of regulatory T cells
(see below). Here again, at least for TCRαβ antibody,
immunosuppression is of the global type and works only
preventively. Regression of diabetes was observed in mice
with recently manifested diabetes [13], which is interest-
ing inasmuch as it provides strong support to the argu-
ment that reversible T-cell-mediated inflammation takes
place in the islets. However, such regression was incon-
sistent and transient (at variance with that induced by anti-
CD3 as described below).
A more selective approach is to target T-cell subsets
using selective TCR Vβ antibodies, on the assumption that
pathogenic T cells preferentially use selective Vβ genes.
Some encouraging but as yet unconfirmed results have
been reported for Vβ8.1 and Vβ6. In fact, the experimental
model in which such Vβ gene restrictive usage was initially
reported, namely experimental allergic encephalomyelitis
[14], has not been confirmed for other experimental
autoimmune diseases. When whole myelin antigens are
used, no clear Vβ gene restrictive usage has been found
in human autoimmune diseases. A special case might be
made for human diabetes for Vβ7 (and perhaps Vβ13),
which are seemingly preferentially used by T cells present
in islet infiltrates [15].
A last and even more specific TCR blockade could be
obtained by immunising against idiotypes of pathogenic T
cells, ideally T-cell clones. This has been attempted in the
NOD mouse either using polyclonal T cells or T-cell
clones, notably clones of anti-hsp60 T cells. Some effect
was reported, but the results, which were often only
partial, require confirmation.
4. Targeting of MHC molecules
Peptides of β cells are presented to T cells in the context
of MHC molecules. It was thus logical to attempt to modu-
late the course of β-cell-specific autoimmunity in NOD
mice targeting MHC molecules. Administration of either
class-I-specific or class-II-specific monoclonal antibodies
in young NOD mice (less than 2 months old) but not older
ones prevents the onset of diabetes. The protection
afforded by class II antibodies is long lasting and resistant
to cyclophosphamide and can be transferred to nonanti-
body-treated mice by T cells. Its precise mode of action,
however, remains elusive. It is noteworthy that NOD trans-
genic mice overexpressing mutated MHC non-NOD class
II genes are protected from diabetes and, again, the pro-
tection can be transferred to wild NOD mice by T cells
from transgenic mice [16,17]. Collectively, these data
suggest that targeting MHC molecules might lead to stim-
ulation of regulatory class II restricted CD4 T cells, which
are as yet uncharacterised.
MHC molecules could also be targeted by blocking
peptide binding to those molecules; this possibility is sug-
gested by the prevention of diabetes that is afforded by
the administration of Iag7 immunogenic but not tolerated
peptide binder. Again, one would have to demonstrate
that the Iag7 binder in question does not act as an altered
peptide ligand (APL) known to stimulate regulatory T cells
in these models.
5. Targeting of costimulation and adhesion molecules
The activation of autoreactive T cells specific to β-cell anti-
gens involves a number of costimulation and adhesion
molecules. Thus, antibodies to B7.1 or to CD40L prevent
the onset of diabetes. CTLA-4–Ig, a fusion protein of
CTLA-4 and IgG Fc, which inhibits the binding of CD28 to
B7, also delays the onset of diabetes. A similar preventive
effect has been reported for an anti-CD28 antibody, but
here the mechanism of action of the antibody probably
relates to an agonistic effect leading to signalling of regu-
latory T cells. In fact, this therapeutic approach is more
generally complicated by the dual effect of some of the
agents used, depending when they are administered.
Thus, CTLA-4–Ig fusion protein prevents the onset of dia-
betes when administered late but accelerates the progres-
sion of the disease when administered early [18].
Note also that CD28–/– and B7–/– NOD mice show fulmi-
nant diabetes, probably because of the absence of regula-
tory T cells [18,19].
Diabetes has also been prevented by blocking adhesion
molecules, particularly using antibodies against intercellu-
lar adhesion molecule (ICAM)-1 and LFA-1. Workers in
this laboratory have recently found that administration of
adenovirus-infected cells producing soluble recombinant
ICAM-1 also protected NOD mice against diabetes. We
have even shown that such gene therapy can reverse
recently established diabetes (P Lemarchand, unpublished
observations).
6. Cytokine blockade
A wide array of cytokines are involved in the differentiation
and activation of the various T-cell subsets contributing to
diabetes pathogenesis in NOD mice. All antibodies
directed at cytokines or cytokine receptors inhibiting the
onset of diabetes relate to Th1 cells. Thus, the onset of dia-
betes is prevented by antibodies directed against IFN-γ, IL-
2 receptor (an association with low-dose cyclosporin A is
required), or IL-12. Interestingly, a similar effect was
obtained by blocking the cytokine receptor with a recep-
tor/immunoglobulin fusion protein or by destroying the
Available online http://arthritis-research.com/content/4/S3/S003S8
receptor-bearing cell with a cytokine-toxin conjugate. The
preventive effect of orally administered IFN-α is interesting
but is difficult to interpret. Also intriguing is the absence of
diabetes prevention in NOD mice genetically deficient in
IFN-γ, IFN-γ receptor, or IL-12 [20–22], a paradox probably
explained by a redundancy of the genes coding for these
cytokines and their receptors. Prevention of diabetes has
been reported after blockade of proinflammatory cytokines,
namely IL-1, IL-6, and tumour necrosis factor (TNF)-α. In
the latter case, the effect was observed only when the neu-
tralising antibody was administered at a very young age.
7. Pharmacologically active cytokines
Many of the strategies resulting in stimulation of regulatory
cells may be assumed to involve the suppressive effect of
cytokines acting either systematically or locally at the islet
level. The onset of diabetes may also be prevented by the
direct administration of regulatory cytokines.
IL-4
Systemic administration of IL-4 can delay the onset of dia-
betes. The effect is not as dramatic as that of other proce-
dures described here, but is nevertheless quite significant.
In fact, the effect is more clear cut when the cytokine is
directly delivered in the islet using either gene therapy or
β-cell-targeted transgenesis.
IL-10
Findings similar to those reported for IL-4 have been
reported for IL-10 after systemic administration of the
recombinant cytokine. Paradoxically, however, the onset of
diabetes is accelerated by intra-islet delivery of IL-10 in
transgenic mice [23] or by systemic administration of an
IL-10–Ig fusion protein [24], possibly due in the latter case
to an unexpected Th2 polarization.
IL-13
A modest but significant delay in the onset of diabetes has
been reportedly achieved by IL-13, another Th2 cytokine.
G-CSF
Granulocyte-colony-stimulating factor (G-CSF) has been
used successfully to protect NOD mice from diabetes, fol-
lowing previous results in this laboratory showing that
G-CSF could prevent systemic lupus erythematosus in
(NZB × NZW)F1 mice [25]. Data collected in these
various models suggest that the effect of G-CSF could
involve Th2 polarisation.
TNF
Contrasting results have been reported for TNF. Given in
the adult NOD mouse, TNF prevents the onset of diabetes
[26] (an observation in keeping with the insulitis accelera-
tion brought about by anti-TNF antibodies). Conversely,
given to newborn NOD mice, TNF accelerates disease
progression [27].
IL-1
IL-1 has been reported to protect NOD mice from the
onset of diabetes. This is a surprising observation,
because IL-1 has been shown to be exquisitely toxic to β
cells and because an Il-1 antagonist has been reported to
protect against diabetes.
IL-12
Again depending on the protocol of administration, IL-12
may accelerate or slow down the progression of diabetes.
Lymphotoxin
Diabetes protection has also been reported for lympho-
toxin and lymphotoxin–receptor fusion protein.
8. Tolerance to soluble β β-cell autoantigens
Many efforts have been made to induce tolerance to can-
didate β-cell autoantigens. Prevention of disease (but not
cure of established disease) has been obtained with
insulin, glutamic acid decarboxylase, and hsp60. In the
case of insulin, evidence indicated that the effect was not
exclusively linked to the hormone’s metabolic activity,
since the disease could be prevented with insulin, meta-
bolically inactive B chain, or inactive analogues. In the
case of hsp60, the antigen is not, strictly speaking, β-cell-
specific, but its overexpression in inflamed β cells leads to
some β-cell-selective expression.
With each of these three antigens, diabetes was pre-
vented by using various routes of administration: subcuta-
neous (+ adjuvant), oral, nasal, intravenous, intrathymic.
Tolerance was also induced by vaccination with antigen-
specific DNA, as well as by transgenic overexpression of
the autoantigen.
At the level of underlying mechanisms, there is no true
antigen-specific tolerance, since the downregulation of
autoimmunity extends to antigens other than the tolero-
gen. Accumulated data show that soluble β-cell autoanti-
gens induce a deviation in immunity towards Th2, with
bystander suppression probably involving local release of
immunosuppressive cytokines [2].
9. Stimulation of regulatory T cells
The diabetogenic autoimmune response is tightly con-
trolled by a variety of regulatory T cells. I have pointed out
how the administration of soluble β-cell autoantigens
could stimulate Th2 cells and prevent the onset of dia-
betes if given when the mice are young enough. Many
other strategies have been used to prevent the onset of
diabetes targeting non-Th2 regulatory T cells. One may
assume, a priori, that most of these strategies are not β-
cell-specific, since they use non-β-cell-related agents. The
possibility cannot be excluded that, at least in some cases,
the induced regulation is β-cell-specific at the effector
level. One may postulate that a nonspecific stimulation
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leads to the activation or boosting of β-cell-specific regula-
tory T cells, whether or not they are of the Th2 type. The
strategies for stimulating regulatory T cells may be classi-
fied according to whether they make use of nondepleting
anti-T-cell monoclonal antibodies, stimulation of innate
immunity, or pathogens, as discussed below.
Nondepleting anti-T-cell monoclonal antibodies
Administration of anti-CD3 antibodies to NOD mice with
recently manifested IDDM induces long-term remission of
the disease. The effect is obtained after brief treatment
(5 days) and does not require the use of the mitogenic whole
autoantibody molecule (nonactivating F(ab′)2 fragments are
tolerogenic) [28,29]. My colleagues and I have recently
obtained data indicating that the effect is mediated by active
tolerance involving TGF-β-dependent CTLA+CD25+ T cells
(L Chatenoud, unpublished observations).
Similar, though less well documented, data have been
reported for nondepleting anti-CD4 antibodies [30], in
keeping with the analogous effect of the same antibodies
in transplantation. [31].
Stimulation of innate immunity
NOD mice show an early deficit in NK (natural killer)
T cells, both quantitatively and qualitatively (deficient IL-4
production) [32]. It was thus logical to attempt to prevent
IDDM in such mice by stimulating the function of NK
T cells. This was recently done by administering a selec-
tive NK-T-cell ligand, the glycolipid α-galactosylceramide.
Interestingly, the protection still applies in some protocols
when the glycolipid is given late, and can inhibit the recur-
rence of disease in diabetic mice with grafts of syngeneic
islets [33].
Stimulation of γδ regulatory T cells has been reported after
intranasal administration of insulin [34]. It will be interest-
ing to learn whether such T cells that protect against dia-
betes after nasal administration of insulin are insulin
specific.
Pathogens
Bacteria. A whole array of bacteria have been shown to
prevent the onset of diabetes in NOD mice. Mycobacteria
have been extensively studied, particularly Mycobacterium
bovis (the source of BCG vaccine) and M. avium. The
effect is also obtained with mycobacteria extracts (in com-
plete Freund’s adjuvant). The role of regulatory T cells in
protection induced by complete Freund’s adjuvant or vac-
cination with BCG is demonstrated by the transfer of pro-
tection that is achieved when CD4 T cells from protected
mice are transferred to naive mice [35]. The nature of the
regulatory cells in question is open to speculation (are
they Th2 cells? CD25 cells?). Other bacterial-cell extracts
have also been shown to prevent the onset of diabetes in
NOD mice, notably extracts of streptococcus or klebsiella.
Viruses. The onset of diabetes in NOD mice can be pre-
vented by infection with various viruses, in partucular lym-
phochoriomeningitis virus (LCMV), murine hepatitis virus
(MHV), and lactate dehydrogenase virus (LDHV).
Parasites. Diabetes can also be prevented by deliberate
administration of parasites, such as schistosomes or filariae.
10. Gene therapy
Gene therapy may be used in many ways to prevent or
cure diabetes in NOD mice. Insulin gene therapy and
related strategies are not discussed in this chapter.
Immune-based gene therapy has been developed along
several lines. One possibility is to overexpress cytokines or
cytokine receptors with the aim of reproducing the phar-
macological effect of the particular molecules. Various
experimental settings have been considered, including
local intra-islet delivery of the cytokine (using transgenic
mice or islet-specific T-cell transfection) and systemic
delivery. Various vectors (viral and nonviral) have been
used. IL-4, IL-4–Ig fusion protein, IL-10, IFN-γ receptor, Ig,
and TGF-β all protected the mice from diabetes.
We recently reported that systemic delivery of soluble ICAM-
1 using a recombinant adenovirus vector could also be pro-
tective and even curative in mice that had recently developed
diabetes (P Lemarchand, unpublished observations).
Less expected is the protective effect of calcitonin gene
therapy.
11. Cell therapy
Islet transplantation
Syngeneic islet transplantation is really a palliative proce-
dure, not an immunotherapeutic one. However, unlike
insulin therapy, it poses the problems of the prevention of
disease relapse on the graft and consequently requires
associated immunotherapy. Many of the procedures
described above have been used to prevent such disease
relapse, e.g. anti-CD3 and anti-CD4 antibodies, soluble
glutamic acid decarboxylase, α-galactosylceramide, and
BCG vaccination. Similar immunological problems will be
met with attempts to regenerate islet cells from ductal
stem cells, as has been recently described. The problem is
even more serious in the case of allogeneic islet transplan-
tation, in which two problems — relapse and allograft
rejection — are combined.
Bone marrow transplantation
Allogeneic bone marrow transplantation. Another
approach consists in replacing the bone marrow T (and B)
cell precursors. This is not an easy approach, because of
the associated allogeneic reaction (graft versus host and
host versus graft). Such alloimmune response could have
a protective effect, probably through the production of
Available online http://arthritis-research.com/content/4/S3/S003S10
immunoregulatory cytokines: this possibility is suggested
by the protection afforded by induction of (usually partial)
allogeneic tolerance in newborn NOD mice, which also
totally protects from diabetes [36].
Syngeneic bone marrow transplantation. More unexpect-
edly, syngeneic bone marrow transplantation may also
afford protection (in conjunction with IL-3), possibly by
resetting immunoregulatory mechanisms that override
effector ones [37].
Infusion of mononuclear cells
Prevention of diabetes has been reported after infusion of
dendritic cells and CD4–/–CD8–/– thymocytes presumably
enriched in NK T cells. It has also been extensively demon-
strated that the onset of diabetes in NOD mice is pre-
vented by administering mature CD4 T cells (either
polyclonal, notably of the CD25 type, or monoclonal).
Intrathymic islet transplantation
Diabetes has been prevented in NOD mice upon
intrathymic grafting of syngeneic or allogeneic islets, either
at birth or within 4 weeks of age. The preventive effect
was associated with a complete absence of insulitis in
most animals. The observations that spleen cells from tol-
erant islet-grafted NOD mice did not transfer diabetes into
immunoincompetent hosts [38] and that cyclophos-
phamide did not break the tolerance in one study [39] are
compatible with a preferential deletional mechanism.
12. Inhibition of β β-cell lesion
Inhibition of the effector mechanisms leading to destruc-
tion of β cells has been attempted with limited success.
Nicotinamide has some protective effect but only at rela-
tively high doses and early in the disease history. Nitric
oxide (NO) inhibitors have also shown some effects as do
antioxidants, pentoxifylline, and rolipram.
Anti-TCR antibodies and CD3 antibodies also deserve
mention here. They probably act, at least in part, by inacti-
vating effector T cells, as is suggested by virtually immedi-
ate reversal of hyperglycaemia after the first injection of
such antibodies [13,28].
13. Miscellaneous
Immunomodulation
Some products known to modulate immune responses
(without showing a clear overall suppressor or stimulator
pattern of activities) prevent the onset of diabetes in NOD
mice. These include linomide, ciamexon, vanadate, vitamin
D3, and D-glucan.
Hormones
Some hormones or related compounds can also prevent
insulitis and the progression of diabetes in NOD mice.
This has notably been reported for androgens, a finding in
keeping with the acceleration of disease seen after castra-
tion in males and the high female/male ratio of affected
mice. The onset of diabetes is also prevented by IGF-I.
Immunomanipulation
Unexpectedly, immunisation against the lupus-associated
idiotype 16/6 protects NOD mice from diabetes. The pro-
tective effect of natural antibodies presumably has a
similar mode of action. The effect of such antibodies is
interesting, but their mode of action is poorly defined.
Diet
Various diets have been shown to slow the progression of
diabetes in NOD mice, notably the low-protein diets. It has
been reported that casein hydrolysate formula does likewise.
Other products
A number of products listed in Table 1 that have an ill-
defined action on the immune system have also been
reported to prevent the onset of diabetes in NOD mice.
Concluding remarks
The number and variety of therapeutic interventions
capable of preventing diabetes represents an unprece-
dented observation in immune pathology. The number of
interventions that work in mice with advanced disease,
and particularly with established diabetes, is much more
limited, indicating that the majority of efficacious treat-
ments are active only at the very early stages of a
chronic process progressing from insulitis to clinical dia-
betes. As has been mentioned above, the only products
that have been shown to arrest the destruction of β cells
in man are those shown to act late in the natural history
of the disease in NOD mice. Nevertheless, the early-
acting procedures may prove useful in combination with
late-acting drugs. One might envision treating patients
who have recently diagnosed diabetes with the late-
acting drugs, followed by administration of early-acting
drugs, which would regain their activity once the immune
homeostasis has been reset. Alternatively, these numer-
ous early-acting compounds could be applied in man
very early if valid prediction could identify subjects at risk
of developing the disease. However, the logistic prob-
lems associated with such prediabetes trials should not
be overlooked (for example, the number of subjects to be
screened and enrolled and the duration of the trial).
Lastly, many of the concepts and therapeutic strategies
described above for IDDM could probably be extrapo-
lated correctly to other autoimmune diseases, notably
rheumatoid arthritis.
Glossary of terms
BB = BioBreeding (rat); BCG = bacille Calmette–Guérin;
NOD = nonobese diabetic (mouse).
Arthritis Research    Vol 4 Suppl 3 BachS11
References
1. Bach JF: Insulin-dependent diabetes mellitus as an autoim-
mune disease. Endocr Rev 1994, 15:516-542. [key review]
2. Bach JF, Chatenoud L: Tolerance to islet autoantigens and
type I diabetes. Annu Rev Immunol 2001,  19:131-161. [key
review]
3. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P,
Du Rostu H, Rodier M, Sirmai J, Lallemand A, Bach JF:
Cyclosporin increases the rate and length of remissions in
insulin-dependent diabetes of recent onset. Results of a mul-
ticentre double-blind trial. Lancet 1986,  2:119-124. [general
reference]
4. The Canadian-European Randomized Control Trial Group:
Cyclosporin-induced remission of IDDM after early interven-
tion. Association of 1 yr of cyclosporin treatment with
enhanced insulin secretion. Diabetes 1988,  37:1574-1582.
[general reference]
5. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR: Beta-cell
function in new-onset type 1 diabetes and immunomodula-
tion with a heat-shock protein peptide (DiaPep277): a ran-
domised, double-blind, phase II trial. Lancet 2001,  358:
1749-1753. [general reference]
6. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E,
Haastert B, Giani G, Kolb H: The Deutsche Nicotinamide Inter-
vention Study: an attempt to prevent type 1 diabetes. DENIS
Group. Diabetes 1998, 47:980-984. [general reference]
7. Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan
Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC,
Lecomte P, Marechaud R, Bougneres P, Charbonnel B, Sai P:
Oral insulin administration and residual beta-cell function in
recent-onset type 1 diabetes: a multicentre randomised con-
trolled trial. Lancet 2000, 356:545-549. [general reference]
8. Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A,
Spera S, Suraci C, Multari G, Cervoni M, Bitti MLM, Matteoli MC,
Marietti G, Ferrazzoli F, Faldetta MRC, Giordano C, Sbriglia M,
Sarugeri E, Ghirlanda G: No effect of oral insulin on residual
beta-cell function in resent-onset Type I diabetes (The
IMDIAB VII). Diabetologia 2000, 43:1000-1004. [general refer-
ence]
9. Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A,
Chase HP: Effect of Bacillus Calmette-Guerin vaccination on
new-onset type 1 diabetes. A randomized clinical study. Dia-
betes Care 1999, 22:1703-1707. [general reference]
10. Weiner HL, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A,
Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA:
Oral tolerance: immunologic mechanisms and treatment of
animal and human organ-specific autoimmune diseases by
oral administration of autoantigens. Annu Rev Immunol 1994,
12:809-837. [key review]
11. Maki T, Ichikawa T, Blanco R, Porter J: Long-term abrogation of
autoimmune diabetes in nonobese diabetic mice by
immunotherapy with anti-lymphocyte serum. Proc Natl Acad
Sci USA 1992, 89:3434-3438. [general reference]
12. Wang Y, Hao L, Gill RG, Lafferty KJ: Autoimmune diabetes in
NOD mouse is L3T4 T-lymphocyte dependent. Diabetes 1987,
36:535-538. [general reference]
13. Sempe P, Bedossa P, Richard MF, Villa MC, Bach JF, Boitard C:
Anti-alpha/beta T cell receptor monoclonal antibody provides
an efficient therapy for autoimmune diabetes in nonobese
diabetic (NOD) mice. Eur J Immunol 1991,  21:1163-1169.
[general reference]
14. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch
GS, Waldor MK, Zamvil SS, McDevitt HO, Steinman L: Limited
heterogeneity of T cell receptors from lymphocytes mediating
autoimmune encephalomyelitis allows specific immune inter-
vention. Cell 1988, 54:263-273. [general reference]
15. Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach
B: A human endogenous retroviral superantigen as candidate
autoimmune gene in type I diabetes. Cell 1997, 90:303-313.
[general reference]
16. Slattery RM, Kjer-Nielsen L, Allison J, Charlton B, Mandel TE,
Miller JF: Prevention of diabetes in non-obese diabetic I-Ak
transgenic mice. Nature 1990, 345:724-726. [general reference]
17. Singer SM, Tisch R, Yang XD, McDevitt HO: An Abd transgene
prevents diabetes in nonobese diabetic mice by inducing reg-
ulatory T cells. Proc Natl Acad Sci USA 1993, 90:9566-9570.
[general reference]
18. Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY,
Fuchs E, Singh B, Thompson CB, Bluestone JA: CD28/B7 reg-
ulation of Th1 and Th2 subsets in the development of
autoimmune diabetes. Immunity 1996,  5:285-293. [general
reference]
19. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe
A, Bluestone JA: B7/CD28 costimulation is essential for the
homeostasis of the CD4+CD25+ immunoregulatory T cells
that control autoimmune diabetes. Immunity 2000,  12:431-
440. [general reference]
20. Hultgren B, Huang XJ, Dybdal N, Stewart TA: Genetic absence
of gamma-interferon delays but does not prevent diabetes in
NOD mice. Diabetes 1996, 45:812-817. [general reference]
21. Serreze DV, Post CM, Chapman HD, Johnson EA, Lu BF,
Rothman PB: Interferon-gamma receptor signaling is dispens-
able in the development of autoimmune type 1 diabetes in
NOD mice. Diabetes 2000, 49:2007-2011. [general reference]
22. Trembleau S, Penna G, Gregori S, Chapman HD, Serreze DV,
Magram J, Adorini L: Pancreas-infiltrating Th1 cells and dia-
betes develop in IL-12-deficient nonobese diabetic mice. J
Immunol 1999, 163:2960-2968. [general reference]
23. Wogensen L, Lee MS, Sarvetnick N: Production of interleukin
10 by islet cells accelerates immune-mediated destruction of
beta cells in nonobese diabetic mice. J Exp Med 1994, 179:
1379-1384. [general reference]
24. Zheng XX, Steele AW, Hancock WW, Stevens AC, Nickerson
PW, Roy-Chaudhury P, Tian Y, Strom TB: A noncytolytic IL-
10/Fc fusion protein prevents diabetes, blocks autoimmunity,
and promotes suppressor phenomena in NOD mice. J
Immunol 1997, 158:4507-4513. [general reference]
25. Zavala F, Masson A, Hadaya K, Ezine S, Schneider E, Babin O,
Bach JF: Granulocyte-colony stimulating factor treatment of
lupus autoimmune disease in MRL-lpr/lpr mice. J Immunol
1999, 163:5125-5132. [general reference]
26. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H: Pre-
vention of diabetes in nonobese diabetic mice by tumor
necrosis factor (TNF): similarities between TNF-alpha and
interleukin 1. Proc Natl Acad Sci USA 1990,  87:968-972.
[general reference]
27. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD,
McDevitt HO: Effect of tumor necrosis factor alpha on insulin-
dependent diabetes mellitus in NOD mice. I. The early devel-
opment of autoimmunity and the diabetogenic process. J Exp
Med 1994, 180:995-1004. [general reference]
28. Chatenoud L, Thervet E, Primo J, Bach JF: Anti-CD3 antibody
induces long-term remission of overt autoimmunity in
nonobese diabetic mice. Proc Natl Acad Sci USA 1994, 91:
123-127. [general reference]
29. Chatenoud L, Primo J, Bach JF: CD3 antibody-induced domi-
nant self tolerance in overtly diabetic NOD mice. J Immunol
1997, 158:2947-2954. [general reference]
30. Hutchings P, O’Reilly L, Parish NM, Waldmann H, Cooke A: The
use of a non-depleting anti-CD4 monoclonal antibody to
reestablish tolerance to beta cells in NOD mice. Eur J Immunol
1992, 22:1913-1918. [general reference]
31. Waldmann H, Cobbold S: How do monoclonal antibodies
induce tolerance? A role for infectious tolerance? Annu Rev
Immunol 1998, 16:619-644. [key review]
32. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C,
Bach JF: Early quantitative and functional deficiency of
NK1(+)- like thymocytes in the NOD mouse. Eur J Immunol
1996, 26:2989-2998. [general reference]
33. Sharif S, Arraeza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV,
Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite de
Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi
M, Lepault F, Lehuen A, Bach JF, Herbelin A: Activation of
natural killer T cells by α α-galactosylceramide treatment pre-
vents the onset and recurrence of autoimmune Type 1 dia-
betes. Nat Med 2001, 7:1057-1062. [general reference]
34. Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K:
Aerosol insulin induces regulatory CD8 gamma delta T cells
that prevent murine insulin-dependent diabetes. J Exp Med
1996, 184:2167-2174. [general reference]
35. Qin HY, Sadelain MW, Hitchon C, Lauzon J, Singh B: Complete
Freund’s adjuvant-induced T cells prevent the development
and adoptive transfer of diabetes in nonobese diabetic mice. J
Immunol 1993, 150:2072-2080. [general reference]
Available online http://arthritis-research.com/content/4/S3/S003S12
36. Bendelac A, Boitard C, Bach JF, Carnaud C: Neonatal induction
of allogeneic tolerance prevents T cell-mediated autoimmu-
nity in NOD mice. Eur J Immunol 1989, 19:611-616. [general
reference]
37. Ito A, Aoyanagi N, Maki T: Regulation of autoimmune diabetes
by interleukin 3-dependent bone marrow-derived cells in NOD
mice. J Autoimmun 1997, 10:331-338. [general reference]
38. Gerling IC, Serreze DV, Christianson SW, Leiter EH: Intrathymic
islet cell transplantation reduces beta-cell autoimmunity and
prevents diabetes in NOD/Lt mice. Diabetes 1992, 41:1672-
1676. [general reference]
39. Charlton B, Taylor-Edwards C, Tisch R, Fathman CG: Prevention
of diabetes and insulitis by neonatal intrathymic islet adminis-
tration in NOD mice. J Autoimmun 1994, 7:549-560. [general
reference]
40. Shizuru JA, Taylor-Edwards C, Banks BA, Gregory AK, Fathman
CG: Immunotherapy of the nonobese diabetic mouse: treat-
ment with an antibody to T-helper lymphocytes. Science 1988,
240:659-662. [general reference]
41. Hutchings PR, Simpson E, O’Reilly LA, Lund T, Waldmann H,
Cooke A: The involvement of Ly2+ T cells in beta cell destruc-
tion. J Autoimmun 1990, 3 (Suppl 1):101-109. [general reference]
42. Weiss L, Slavin S, Reich S, Cohen P, Shuster S, Stern R,
Kaganovsky E, Okon E, Rubinstein AM, Naor D: Induction of
resistance to diabetes in non-obese diabetic mice by target-
ing CD44 with a specific monoclonal antibody. Proc Natl Acad
Sci USA 2000, 97:285-290. [general reference]
43. Sempe P, Ezine S, Marvel J, Bedossa P, Richard MF, Bach JF,
Boitard C: Role of CD4+CD45RA+ T cells in the development
of autoimmune diabetes in the non-obese diabetic (NOD)
mouse. Int Immunol 1993, 5:479-489. [general reference]
44. Abu-Hadid MM, Lazarovits AI, Madrenas J: Prevention of dia-
betes mellitus in the non-obese diabetic mouse strain with
monoclonal antibodies against the CD45RB molecule. Autoim-
munity 2000, 32:73-76. [general reference]
45. Harada M, Makino S: Suppression of overt diabetes in NOD
mice by anti-thymocyte serum or anti-Thy 1, 2 antibody. Jikken
Dobutsu 1986, 4:501-504. [general reference]
46. Ogawa M, Maruyama T, Hasegawa T, Kanaya T, Kobayashi F,
Tochino Y, Uda H: The inhibitory effect of neonatal thymec-
tomy on the incidence of insulitis in non-obese diabetic
(NOD) mice. Biomed Res 1985, 6:103-105. [general reference]
47. Johnson GG, Mikulowska A, Butcher EC, McEvoy LM, Michie SA:
Anti-CD43 monoclonal antibody L11 blocks migration of T
cells to inflamed pancreatic islets and prevents development
of diabetes in nonobese diabetic mice. J Immunol 1999, 163:
5678-5685. [general reference]
48. Tsukamoto K, Yokono K, Amano K, Nagata M, Yagi N, Tominaga
Y, Moriyama H, Miki M, Okamoto N, Yoneda R: Administration of
monoclonal antibodies against vascular cell adhesion mole-
cule-1/very late antigen-4 abrogates predisposing autoim-
mune diabetes in NOD mice. Cell Immunol 1995, 165:193-201.
[general reference]
49. Yang XD, Karin N, Tisch R, Steinman L, McDevitt HO: Inhibition
of insulitis and prevention of diabetes in nonobese diabetic
mice by blocking L-selectin and very late antigen 4 adhesion
receptors. Proc Natl Acad Sci USA 1993,  90:10494-10498.
[general reference]
50. Jakubowski A, Ehrenfels BN, Pepinsky RB, Burkly LC: Vascular
cell adhesion molecule-Ig fusion protein selectively targets
activated alpha 4-integrin receptors in vivo. Inhibition of
autoimmune diabetes in an adoptive transfer model in
nonobese diabetic mice. J Immunol 1995,  155:938-946.
[general reference]
51. Mori Y, Suko M, Okudaira H, Matsuba I, Tsuruoka A, Sasaki A,
Yokoyama H, Tanase T, Shida T, Nishimura M, Terada E, Ikeda Y:
Preventive effects of cyclosporin on diabetes in NOD mice.
Diabetologia 1986, 29:244-247. [general reference]
52. Miyagawa J, Yamamoto K, Hanafusa T, Itoh N, Nakagawa C,
Otsuka A, Katsura H, Yamagata K, Miyazaki A, Kono N, Tarui S:
Preventive effect of a new immunosuppressant FK-506 on
insulitis and diabetes in non-obese diabetic mice. Diabetologia
1990, 33:503-505. [general reference]
53. Calafiore R, Basta G, Falorni A, Pietropaolo M, Picchio ML, Calci-
naro F, Brunetti P: Preventive effects of azathioprine (AZA) on
the onset of diabetes mellitus in NOD mice. J Endocrinol
Invest 1993, 16:869-873. [general reference]
54. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM:
Rapamycin prevents the onset of insulin-dependent diabetes
mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992, 89:174-
178. [general reference]
55. Nicoletti F, Borghi MO, Meroni PL, Barcellini W, Fain C, Di Marco
R, Menta R, Schorlemmer HU, Bruno G, Magro G, Grasso S: Pre-
vention of cyclophosphamide-induced diabetes in the
NOD/WEHI mouse with deoxyspergualin. Clin Exp Immunol
1993, 91:232-236. [general reference]
56. Takahashi M, Kojima S, Yamaoka K, Niki E: Prevention of type I
diabetes by low-dose gamma irradiation in NOD mice. Radiat
Res 2000, 154:680-685. [general reference]
57. Bacelj A, Charlton B, Mandel TE: Prevention of cyclophos-
phamide-induced diabetes by anti-V beta 8 T-lymphocyte-
receptor monoclonal antibody therapy in NOD/Wehi mice.
Diabetes 1989, 38:1492-1495. [general reference]
58. Gearon CL, Hussain MJ, Vergani D, Peakman M: Lymphocyte
vaccination protects prediabetic non-obese diabetic mice
from developing diabetes mellitus. Diabetologia 1997,  40:
1388-1395. [general reference]
59. Smerdon RA, Peakman M, Hussain MJ, Vergani D: Lymphocyte
vaccination prevents spontaneous diabetes in the non-obese
diabetic mouse. Immunology 1993, 80:498-501. [general refer-
ence]
60. Formby B, Shao T: T cell vaccination against autoimmune dia-
betes in nonobese diabetic mice. Ann Clin Lab Sci 1993, 23:
137-147. [general reference]
61. Feili-Hariri M, Frantz MO, Morel PA: Prevention of diabetes in
the NOD mouse by a Th1 clone specific for a hsp60 peptide. J
Autoimmun 2000, 14:133-142. [general reference]
62. Vaysburd M, Lock C, McDevitt H: Prevention of insulin-depen-
dent diabetes mellitus in nonobese diabetic mice by immuno-
genic but not by tolerated peptides. J Exp Med 1995,  182:
897-902. [general reference]
63. Taki T, Nagata M, Ogawa W, Hatamori N, Hayakawa M, Hari J,
Shii K, Baba S, Yokono K: Prevention of cyclophosphamide-
induced and spontaneous diabetes in NOD/Shi/Kbe mice by
anti-MHC class I Kd monoclonal antibody. Diabetes 1991, 40:
1203-1209. [general reference]
64. Boitard C, Bendelac A, Richard MF, Carnaud C, Bach JF: Pre-
vention of diabetes in nonobese diabetic mice by anti-I-A
monoclonal antibodies: transfer of protection by splenic T
cells. Proc Natl Acad Sci USA 1988, 85:9719-9723. [general
reference]
65. Miyazaki T, Matsuda Y, Toyonaga T, Miyazaki J, Yazaki Y, Yama-
mura K: Prevention of autoimmune insulitis in nonobese dia-
betic mice by expression of major histocompatibility complex
class I Ld molecules. Proc Natl Acad Sci USA 1992, 89:9519-
9523. [general reference]
66. Singer SM, Tisch R, Yang XD, Sytwu HK, Liblau R, McDevitt HO:
Prevention of diabetes in NOD mice by a mutated I-Ab trans-
gene. Diabetes 1998, 47:1570-1577. [general reference]
67. Nishimoto H, Kikutani H, Yamamura K, Kishimoto T: Prevention of
autoimmune insulitis by expression of I-E molecules in NOD
mice. Nature 1987, 328:432-434. [general reference]
68. Arreaza GA, Cameron MJ, Jaramillo A, Gill BM, Hardy D, Laupland
KB, Rapoport MJ, Zucker P, Chakrabarti S, Chensue SW, Qin HY,
Singh B, Delovitch TL: Neonatal activation of CD28 signaling
overcomes T cell anergy and prevents autoimmune diabetes
by an IL-4-dependent mechanism. J Clin Invest 1997,  100:
2243-2253. [general reference]
69. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N,
Herold KC, Bluestone JA: Differential effects of anti-B7-1 and
anti-B7-2 monoclonal antibody treatment on the development
of diabetes in the nonobese diabetic mouse. J Exp Med 1995,
181:1145-1155. [general reference]
70. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO,
Sarvetnick N: CD40 ligand-CD40 interactions are necessary
for the initiation of insulitis and diabetes in nonobese diabetic
mice. J Immunol 1997, 159:4620-4627. [general reference]
71. Hasegawa Y, Yokono K, Taki T, Amano K, Tominaga Y, Yoneda R,
Yagi N, Maeda S, Yagita H, Okumura K, Kasuga M: Prevention of
autoimmune insulin-dependent diabetes in non-obese dia-
betic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol
1994, 6:831-838. [general reference]
72. Martin S, Heidenthal E, Schulte B, Rothe H, Kolb H: Soluble
forms of intercellular adhesion molecule-1 inhibit insulitis and
Arthritis Research    Vol 4 Suppl 3 BachS13
onset of autoimmune diabetes. Diabetologia 1998, 41:1298-
1303. [general reference]
73. Hutchings P, Rosen H, O’Reilly L, Simpson E, Gordon S, Cooke
A:  Transfer of diabetes in mice prevented by blockade of
adhesion-promoting receptor on macrophages. Nature 1990,
348:639-642. [general reference]
74. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I,
Bedossa P, Bach JF: Prevention of diabetes in NOD mice
treated with antibody to murine IFN gamma. J Autoimmun
1991, 4:237-248. [general reference]
75. Campbell IL, Kay TW, Oxbrow L, Harrison LC: Essential role for
interferon-gamma and interleukin-6 in autoimmune insulin-
dependent diabetes in NOD/Wehi mice. J Clin Invest 1991, 87:
739-742. [general reference]
76. Prudhomme GJ, Chang Y: Prevention of autoimmune diabetes
by intramuscular gene therapy with a nonviral vector encod-
ing an interferon-gamma receptor/IgG1 fusion protein. Gene
Ther 1999, 6:771-777. [general reference]
77. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom
TB: Anti-interleukin 2 receptor antibody suppresses murine
diabetic insulitis and lupus nephritis. J Immunol 1988, 140:59-
61. [general reference]
78. Zheng XX, Steele AW, Hancock WW, Kawamoto K, Li XC, Nick-
erson PW, Li Y, Tian Y, Strom TB: IL-2 receptor-targeted
cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic
autoimmunity in nonobese diabetic mice. J Immunol 1999,
163:4041-4048. [general reference]
79. Pacheco-Silva A, Bastos MG, Muggia RA, Pankewycz O, Nichols
J, Murphy JR, Strom TB, Rubin-Kelley VE: Interleukin 2 receptor
targeted fusion toxin (DAB486-IL-2) treatment blocks dia-
betogenic autoimmunity in non-obese diabetic mice. Eur J
Immunol 1992, 22:697-702. [general reference]
80. Fujihira K, Nagata M, Moriyama H, Yasuda H, Arisawa K,
Nakayama M, Maeda S, Kasuga M, Okumura K, Yagita H, Yokono
K: Suppression and acceleration of autoimmune diabetes by
neutralization of endogenous interleukin-12 in NOD mice. Dia-
betes 2000, 49:1998-2006. [general reference]
81. Rothe H, O’Hara RM Jr, Martin S, Kolb H: Suppression of
cyclophosphamide induced diabetes development and pan-
creatic Th1 reactivity in NOD mice treated with the interleukin
(IL)-12 antagonist IL-12(p40)2. Diabetologia 1997, 40:641-646.
[general reference]
82. Brod SA, Malone M, Darcan S, Papolla M, Nelson L: Ingested
interferon alpha suppresses type I diabetes in non-obese dia-
betic mice. Diabetologia 1998, 41:1227-1232. [general reference]
83. Cailleau C, Diu-Hercend A, Ruuth E, Westwood R, Carnaud C:
Treatment with neutralizing antibodies specific for IL-1beta
prevents cyclophosphamide-induced diabetes in nonobese
diabetic mice. Diabetes 1997, 46:937-940. [general reference]
84. Sandberg JO, Eizirik DL, Sandler S: IL-1 receptor antagonist
inhibits recurrence of disease after syngeneic pancreatic
islet transplantation to spontaneously diabetic non-obese
diabetic (NOD) mice. Clin Exp Immunol 1997, 108:314-317.
[general reference]
85. Wu Q, Salomon B, Chen M, Wang Y, Hoffman LM, Bluestone JA,
Fu YX: Reversal of spontaneous autoimmune insulitis in
nonobese diabetic mice by soluble lymphotoxin receptor. J
Exp Med 2001, 193:1327-1332. [general reference]
86. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter
EH, Cyopick P, Danska JS, Delovitch TL: Interleukin 4 reverses
T cell proliferative unresponsiveness and prevents the onset
of diabetes in nonobese diabetic mice. J Exp Med 1993, 178:
87-99. [general reference]
87. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC,
Power RF, Rajotte RV: Combined therapy with interleukin-4
and interleukin-10 inhibits autoimmune diabetes recurrence
in syngeneic islet-transplanted nonobese diabetic mice.
Analysis of cytokine mRNA expression in the graft. Transplan-
tation 1995, 60:368-374. [general reference]
88. Pennline KJ, Roque-Gaffney E, Monahan M: Recombinant
human IL-10 prevents the onset of diabetes in the nonobese
diabetic mouse. Clin Immunol Immunopathol 1994,  71:169-
175. [general reference]
89. Zaccone P, Phillips J, Conget I, Gomis R, Haskins K, Minty A,
Bendtzen K, Cooke A, Nicoletti F: Interleukin-13 prevents
autoimmune diabetes in NOD mice. Diabetes 1999, 48:1522-
1528. [general reference]
90. Kim JY, Cho SH, Kim YW, Jang EC, Park SY, Kim EJ, Lee SK:
Effects of BCG, lymphotoxin and bee venom on insulitis and
development of IDDM in non-obese diabetic mice. J Kor Med
Sci 1999, 14:648-652. [general reference]
91. Nicoletti F, Zaccone P, Conget I, Gomis R, Moller C, Meroni PL,
Bendtzen K, Trepicchio W, Sandler S: Early prophylaxis with
recombinant human interleukin-11 prevents spontaneous
diabetes in NOD mice. Diabetes 1999, 48:2333-2339. [general
reference]
92. Formby B, Jacobs C, Dubuc P, Shao T: Exogenous administra-
tion of IL-1 alpha inhibits active and adoptive transfer autoim-
mune diabetes in NOD mice. Autoimmunity 1992,  12:21-27.
[general reference]
93. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL: Suppression of
diabetes in nonobese diabetic mice by oral administration of
porcine insulin. Proc Natl Acad Sci USA 1991,  88:10252-
10256. [general reference]
94. Slavin AJ, Maron R, Weiner HL: Mucosal administration of IL-10
enhances oral tolerance in autoimmune encephalomyelitis
and diabetes. Int Immunol 2001,  13:825-833. [general refer-
ence]
95. Daniel D, Wegmann DR: Protection of nonobese diabetic mice
from diabetes by intranasal or subcutaneous administration
of insulin peptide B-(9-23). Proc Natl Acad Sci USA 1996, 93:
956-960. [general reference]
96. Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta
R, Krischer J, MacLaren N: Insulin immunization of nonobese
diabetic mice induces a protective insulitis characterized by
diminished intraislet interferon-gamma transcription. J Clin
Invest 1995, 95:628-634. [general reference]
97. Karounos DG, Bryson JS, Cohen DA: Metabolically inactive
insulin analog prevents type I diabetes in prediabetic NOD
mice. J Clin Invest 1997, 100:1344-1348. [general reference]
98. Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L,
Fathman CG: Immunization with DNA encoding an immun-
odominant peptide of insulin prevents diabetes in NOD mice.
Clin Immunol 2001, 100:164-171. [general reference]
99. French MB, Allison J, Cram DS, Thomas HE, Dempsey-Collier M,
Silva A, Georgiou HM, Kay TW, Harrison LC, Lew AM: Trans-
genic expression of mouse proinsulin II prevents diabetes in
nonobese diabetic mice. Diabetes 1997,  46:34-39. [general
reference]
100.Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lind-
blad M, Mayer A, Czerkinsky C, Holmgren J, Thivolet C: A cholera
toxoid-insulin conjugate as an oral vaccine against sponta-
neous autoimmune diabetes. Proc Natl Acad Sci USA 1997,
94:4610-4614. [general reference]
101.Ramiya VK, Shang XZ, Wasserfall CH, MacLaren NK: Effect of oral
and intravenous insulin and glutamic acid decarboxylase in
NOD mice. Autoimmunity 1997, 26:139-151. [general reference]
102.Tian J, Atkinson MA, Clare Salzler M, Herschenfeld A, Forsthuber
T, Lehmann PV, Kaufman DL: Nasal administration of glutamate
decarboxylase (GAD65) peptides induces Th2 responses and
prevents murine insulin-dependent diabetes. J Exp Med 1996,
183:1561-1567. [general reference]
103.Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GSP,
Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV:
Spontaneous loss of T-cell tolerance to glutamic acid decar-
boxylase in murine insulin-dependent diabetes. Nature 1993,
366:69-72. [general reference]
104.Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO:
Immune response to glutamic acid decarboxylase correlates
with insulitis in non-obese diabetic mice. Nature 1993, 366:72-
75. [general reference]
105.Filippova M, Liu J, Escher A: Effects of plasmid DNA injection
on cyclophosphamide-accelerated diabetes in NOD mice.
DNA Cell Biol 2001, 20:175-81. [general reference]
106.Menard V, Jacobs H, Jun HS, Yoon JW, Kim SW: Anti-GAD mon-
oclonal antibody delays the onset of diabetes mellitus in NOD
mice. Pharmaceut Res 1999, 16:1059-1066. [general reference]
107.Elias D, Markovits D, Reshef T, Van Der Zee R, Cohen IR: Induc-
tion and therapy of autoimmune diabetes in the non-obese
diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. Proc
Natl Acad Sci USA 1990, 87:1576-1580. [general reference]
108.Elias D, Meilin A, Ablamunits V, Birk OS, Carmi P, Konen-
Waisman S, Cohen IR: Hsp60 peptide therapy of NOD mouse
diabetes induces a Th2 cytokine burst and downregulates
Available online http://arthritis-research.com/content/4/S3/S003S14
autoimmunity to various beta-cell antigens. Diabetes 1997,
46:758-764. [general reference]
109.Elias D, Cohen IR: Peptide therapy for diabetes in NOD mice.
Lancet 1994, 343:704-706. [general reference]
110.Birk OS, Douek DC, Elias D, Takacs K, Dewchand H, Gur SL,
Walker MD, Van Der Zee R, Cohen IR, Altmann DM: A role of
hsp60 in autoimmune diabetes: analysis in a transgenic
model. Proc Natl Acad Sci USA 1996, 93:1032-1037. [general
reference]
111.Reddy S, Stefanovic N, Karanam M: Prevention of autoimmune
diabetes by oral administration of syngeneic pancreatic
extract to young NOD mice. Pancreas 2000, 20:55-60. [general
reference]
112.Yagi H, Matsumoto M, Kishimoto Y, Makino S, Harada M: Possi-
ble mechanism of the preventive effect of BCG against dia-
betes mellitus in NOD mouse. II. Suppression of
pathogenesis by macrophage transfer from BCG-vaccinated
mice. Cell Immunol 1991, 138:142-149. [general reference]
113.Bras A, Aguas AP: Diabetes-prone NOD mice are resistant to
Mycobacterium avium and the infection prevents autoimmune
disease. Immunology 1996, 89:20-25. [general reference]
114.Sadelain MW, Qin HY, Lauzon J, Singh B: Prevention of type I
diabetes in NOD mice by adjuvant immunotherapy. Diabetes
1990, 39:583-589. [general reference]
115.Matsuzaki T, Nagata Y, Kado S, Uchida K, Kato I, Hashimoto S,
Yokokura T: Prevention of onset in an insulin-dependent dia-
betes mellitus model, NOD mice, by oral feeding of Lacto-
bacillus casei. APMIS 1997, 105:643-649. [general reference]
116.Toyota T, Satoh J, Oya K, Shintani S, Okano T: Streptococcal
preparation (OK-432) inhibits development of type I diabetes
in NOD mice. Diabetes 1986, 35:496-499. [general reference]
117.Sai P, Rivereau AS: Prevention of diabetes in the nonobese
diabetic mouse by oral immunological treatments. Compara-
tive efficiency of human insulin and two bacterial antigens,
lipopolysacharide from Escherichia coli and glycoprotein
extract from Klebsiella pneumoniae. Diabetes Metab 1996, 22:
341-348. [general reference]
118.Hartmann B, Bellmann K, Ghiea I, Kleemann R, Kolb H: Oral
insulin for diabetes prevention in NOD mice: potentiation by
enhancing Th2 cytokine expression in the gut through bacter-
ial adjuvant. Diabetologia 1997, 40:902-909. [general reference]
119.Wilberz S, Partke HJ, Dagnaes-Hansen F, Herberg L: Persistent
MHV (mouse hepatitis virus) infection reduces the incidence
of diabetes mellitus in non-obese diabetic mice. Diabetologia
1991, 34:2-5. [general reference]
120.Takei I, Asaba Y, Kasatani T, Maruyama T, Watanabe K, Yana-
gawa T, Saruta T, Ishii T: Suppression of development of dia-
betes in NOD mice by lactate dehydrogenase virus infection. J
Autoimmun 1992, 5:665-673. [general reference]
121.Oldstone MB: Viruses as therapeutic agents. I. Treatment of
nonobese insulin-dependent diabetes mice with virus pre-
vents insulin-dependent diabetes mellitus while maintaining
general immune competence. J Exp Med 1990,  171:2077-
2089. [general reference]
122.Imai S, Tezuka H, Fujita K: A factor of inducing IgE from a filarial
parasite prevents insulin-dependent diabetes mellitus in
nonobese diabetic mice. Biochem Biophys Res Comm 2001,
286:1051-1058. [general reference]
123.Cooke A, Tonks P, Jones FM, O’Shea H, Hutchings P, Fulford AJ,
Dunne DW: Infection with Schistosoma mansoni prevents
insulin dependent diabetes mellitus in non-obese diabetic
mice. Parasite Immunol 1999, 21:169-176. [general reference]
124.Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV,
Miura T, Haba T, Scherer DC, Wei J, Kronenberg M, Koezuka Y,
Van Kaer L: The natural killer T-cell ligand alpha-galactosylce-
ramide prevents autoimmune diabetes in non-obese diabetic
mice. Nat Med 2001, 7:1052-1056. [general reference]
125.Kawamura T, Nagata M, Utsugi T, Yoon JW: Prevention of
autoimmune type I diabetes by CD4+ suppressor T cells in
superantigen-treated non-obese diabetic mice. J Immunol
1993, 151:4362-4370. [general reference]
126.Tisch R, Wang B, Weaver DJ, Liu S, Bui T, Arthos J, Serreze DV:
Antigen-specific mediated suppression of beta cell autoim-
munity by plasmid DNA vaccination. J Immunol 2001,  166:
2122-2132. [general reference]
127.Yamamoto AM, Chernajovsky Y, Lepault F, Podhajcer O, Feld-
mann M, Bach JF, Chatenoud L: The activity of immunoregula-
tory T cells mediating active tolerance is potentiated in
nonobese diabetic mice by an IL4-based retroviral gene
therapy. J Immunol 2001, 166:4973-4980. [general reference]
128.Cameron MJ, Strathdee CA, Holmes KD, Arreaza GA, Dekaban
GA, Delovitch TL: Biolistic-mediated interleukin 4 gene trans-
fer prevents the onset of type 1 diabetes. Hum Gene Ther
2000, 11:1647-1656. [general reference]
129.Cameron MJ, Arreaza GA, Waldhauser L, Gauldie J, Delovitch TL:
Immunotherapy of spontaneous type I diabetes in nonobese
diabetic mice by systemic interleukin-4 treatment employing
adenovirus vector-mediated gene transfer. Gene Ther 2000, 7:
1840-1846. [general reference]
130.Chang YG, Prudhomme GJ: Intramuscular administration of
expression plasmids encoding interferon-gamma receptor/
IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmu-
nity. J Gene Med 1999, 1:415-423. [general reference]
131.Moritani M, Yoshimoto K, Ii S, Kondo M, Iwahana H, Yamaoka T,
Sano T, Nakano N, Kikutani H, Itakura M: Prevention of adop-
tively transferred diabetes in nonobese diabetic mice with IL-
10-transduced islet-specific Th1 lymphocytes - A gene
therapy model for autoimmune diabetes. J Clin Invest 1996,
98:1851-1859. [general reference]
132.Kawamoto S, Nitta Y, Tashiro F, Nakano A, Yamato E, Tahara H,
Tabayashi K, Miyazaki J: Suppression of T(h)1 cell activation
and prevention of autoimmune diabetes in NOD mice by local
expression of viral IL-10. Int Immunol 2001,  13:685-694.
[general reference]
133.Koh JJ, Ko KS, Lee M, Han S, Park JS, Kim SW: Degradable
polymeric carrier for the delivery of IL-10 plasmid DNA to
prevent autoimmune insulitis of NOD mice. Gene Ther 2000,
7:2099-2104. [general reference]
134.Piccirillo CA, Chang YG, Prudhomme GJ: TGF-beta 1 somatic
gene therapy prevents autoimmune disease in nonobese dia-
betic mice. J Immunol 1998, 161:3950-3956. [general reference]
135.Khachatryan A, Guerder S, Palluault F, Cote G, Solimena M,
Valentijn K, Millet I, Flavell RA, Vignery A: Targeted expression of
the neuropeptide calcitonin gene-related peptide to beta cells
prevents diabetes in NOD mice. J Immunol 1997, 158:1409-
1416. [general reference]
136.Mottram PL, Murray-Segal LJ, Han W, Maguire J, Stein-Oakley A,
Mandel TE: Long-term survival of segmental pancreas iso-
grafts in NOD/Lt mice treated with anti-CD4 and anti-CD8
monoclonal antibodies. Diabetes 1998, 47:1399-1405. [general
reference]
137.Yasumizu R, Sugiura K, Iwai H, Inaba M, Makino S, Ida T, Imura H,
Hamashima Y, Good RA, Ikehara S: Treatment of type 1 dia-
betes mellitus in non-obese diabetic mice by transplantation
of allogeneic bone marrow and pancreatic tissue. Proc Natl
Acad Sci USA 1987, 84:6555-6557. [general reference]
138.Mathieu C, Casteels K, Bouillon R, Waer M: Protection against
autoimmune diabetes in mixed bone marrow chimeras:
mechanisms involved. J Immunol 1997,  158:1453-1457.
[general reference]
139.Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel
PA: Immunotherapy of NOD mice with bone marrow-derived
dendritic cells. Diabetes 1999,  48:2300-2308. [general
reference]
140.Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C: Pre-
vention of diabetes in nonobese diabetic mice by dendritic
cell transfer. J Clin Invest 1992, 90:741-748. [general reference]
141.Hammond KJ, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI,
Baxter AG: Alpha/beta-T cell receptor (TCR)(+)CD4(-)CD8(-)
(NKT) thymocytes prevent insulin-dependent diabetes melli-
tus in nonobese diabetic (NOD)/Lt mice by the influence of
interleukin (IL)-4 and/or IL-10. J Exp Med 1998,  187:1047-
1056. [general reference]
142.Boitard C, Yasunami R, Dardenne M, Bach JF: T cell-mediated
inhibition of the transfer of autoimmune diabetes in NOD
mice. J Exp Med 1989, 169:1669-1680. [general reference]
143.Chosich N, Harrison LC: Suppression of diabetes mellitus in
the non-obese diabetic (NOD) mouse by an autoreactive
(anti-I-Ag7) islet-derived CD4+ T-cell line. Diabetologia 1993,
36:716-721. [general reference]
144.Georgiou HM, Constantinou D, Mandel TE: Prevention of
autoimmunity in nonobese diabetic (NOD) mice by neonatal
transfer of allogeneic thymic macrophages. Autoimmunity
1995, 21:89-97. [general reference]
Arthritis Research    Vol 4 Suppl 3 BachS15
145.Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarui
S:  Preventive and therapeutic effects of large-dose nicoti-
namide injections on diabetes associated with insulitis. An
observation in nonobese diabetic (NOD) mice. Diabetes 1982,
31:749-753. [general reference]
146.Hayward AR, Shriber M, Sokol R: Vitamin E supplementation
reduces the incidence of diabetes but not insulitis in NOD
mice. J Lab Clin Med 1992, 119:503-507. [general reference]
147.Heineke EW, Johnson MB, Dillberger JE, Robinson KM: Antioxi-
dant MDL 29,311 prevents diabetes in nonobese diabetic and
multiple low-dose STZ-injected mice. Diabetes 1993, 42:1721-
1730. [general reference]
148.Rabinovitch A, Suarez WL, Power RF: Combination therapy with
an antioxidant and a corticosteroid prevents autoimmune dia-
betes in NOD mice. Life Sci 1992,  51:1937-1943. [general
reference]
149.Corbett JA, Mikhael A, Shimizu J, Frederick K, Misko TP, McDaniel
ML, Kanagawa O, Unanue ER: Nitric oxide production in islets
from nonobese diabetic mice: aminoguanidine-sensitive and -
resistant stages in the immunological diabetic process. Proc
Natl Acad Sci USA 1993, 90:8992-8995. [general reference]
150.Liang L, Beshay E, Prud’Homme GJ: The phosphodiesterase
inhibitors pentoxifylline and rolipram prevent diabetes in NOD
mice. Diabetes 1998, 47:570-575. [general reference]
151.Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S:
Prevention of diabetes mellitus in non-obese diabetic mice by
Linomide, a novel immunomodulating drug. Diabetologia
1994, 37:1195-1201. [general reference]
152.Kino K, Mizumoto K, Sone T, Yamaji T, Watanabe J, Yamashita A,
Yamaoka K, Shimizu K, Ko K, Tsunoo H: An immunomodulating
protein, Ling Zhi-8 (LZ-8) prevents insulitis in non-obese dia-
betic mice. Diabetologia 1990, 33:713-718. [general reference]
153.Kida K, Kaino Y, Ito T, Hirai H: Controversies on the prevention
of insulin-dependent diabetes mellitus by immunomodula-
tion: lessons from NOD mice treated with beta-1,6;1,3-D-
glucan and rhIGF-I. J Pediatr Endocrinol Metab 1998, 11 (Suppl
2):327-333. [general reference]
154.Panerai AE, Nicoletti F, Sacedote P, Arvidsson L, Conget I, Gomis
R, Bartorelli A, Sandler S: MFP14, a multifunctional emerging
protein with immunomodulatory properties, prevents sponta-
neous and recurrent autoimmune diabetes in NOD mice. Dia-
betologia 2001, 44:839-47. [general reference]
155.Krug J, Lampeter EF, Williams AJ, Procaccini E, Cartledge C,
Signore A, Beales PE, Pozzilli P: Immunotherapy with ciamexon
in the non obese diabetic (NOD) mouse. Hormone Metab Res
1992, 24:1-4. [general reference]
156.Burkart V, Kim Y, Kauer M, Kolb H: Induction of tolerance in
macrophages by cholera toxin B chain. Pathobiology 1999, 67:
314-317. [general reference]
157.Sobel DO, Yankelevich B, Goyal D, Nelson D, Mazumder A: The
B-subunit of cholera toxin induces immunoregulatory cells
and prevents diabetes in the NOD mouse. Diabetes 1998, 47:
186-191. [general reference]
158.Meyerovitch J, Waner T, Sack J, Kopolovic J, Shemer J: Attempt
to prevent the development of diabetes in non-obese diabetic
mice by oral vanadate administration. Israel Med Assoc J
2000, 2:211-214. [general reference]
159.Casteels KM, Mathieu C, Waer M, Valckx D, Overbergh L, Laureys
JM, Bouillon R: Prevention of type I diabetes in nonobese dia-
betic mice by late intervention with nonhypercalcemic
analogs of 1,25-dihydroxyvitamin D-3 in combination with a
short induction course of cyclosporin A. Endocrinology 1998,
139:95-102. [general reference]
160.Fox HS: Androgen treatment prevents diabetes in nonobese
diabetic mice. J Exp Med 1992,  175:1409-1412. [general
reference]
161.Andersson A, Forsgren S, Soderstrom A, Holmberg D: Mono-
clonal, natural antibodies prevent development of diabetes in
the non-obese diabetic (NOD) mouse. J Autoimmun 1991, 4:
733-742. [general reference]
162.Forsgren S, Andersson A, Hillorn V, Soderstrom A, Holmberg D:
Immunoglobulin-mediated prevention of autoimmune dia-
betes in the non-obese diabetic (NOD) mouse. Scand J
Immunol 1991, 34:445-451. [general reference]
163.Krause I, Tomer Y, Elias D, Blank M, Gilburd B, Cohen IR, Shoen-
feld Y: Inhibition of diabetes in NOD mice by idiotypic induc-
tion of SLE. J Autoimmun 1999, 13:49-55. [general reference]
164.Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, Kaufman DL:
Lipopolysaccharide-activated B cells down-regulate Th1
immunity and prevent autoimmune diabetes in nonobese dia-
betic mice. J Immunol 2001, 167:1081-1089. [general reference]
165.Iguchi M, Inagawa H, Nishizawa T, Okutomi T, Morikawa A, Soma
GI, Mizuno D: Homeostasis as regulated by activated
macrophage. V. Suppression of diabetes mellitus in non-
obese diabetic mice by LPSw (a lipopolysaccharide from
wheat flour). Chem Pharmaceut Bull 1992,  40:1004-1006.
[general reference]
166.Hermitte L, Atlan-Gepner C, Payan MJ, Mehelleb M, Vialettes B:
Dietary protection against diabetes in NOD mice: lack of a
major change in the immune system. Diabete Metab 1995, 21:
261-268. [general reference]
167.Hoorfar J, Buschard K, Dagnaes Hansen F: Prophylactic nutri-
tional modification of the incidence of diabetes in autoim-
mune non-obese diabetic (NOD) mice. Br J Nutr 1993,  69:
597-607. [general reference]
168.Buschard K, Hanspers K, Fredman P, Reich EP: Treatment with
sulfatide or its precursor, galactosylceramide, prevents
diabetes in NOD mice. Autoimmunity 2001, 34:9-17. [general
reference]
169.Kobayashi T, Song QH, Hong T, Kitamura H, Cyong JC: Preven-
tive effect of Ninjin-to (Ren-Shen-Tang), a Kampo (Japanese
traditional) formulation, on spontaneous autoimmune dia-
betes in non-obese diabetic (NOD) mice. Microbiol Immunol
2000, 44:299-305. [general reference]
170.Charlton B, Bacelj A, Mandel TE: Administration of silica parti-
cles or anti-Lyt2 antibody prevents beta-cell destruction in
NOD mice given cyclophosphamide. Diabetes 1988, 37:930-
935. [general reference]
171.Wilberz S, Herberg L, Renold AE: Gangliosides in vivo reduce
diabetes incidence in non-obese diabetic mice. Diabetologia
1988, 31:855-857. [general reference]
172.Maruyama T, Watanabe K, Takei I, Kasuga A, Shimada A,
Yanagawa T, Kasatani T, Suzuki Y, Kataoka K, Saruta T: Anti-
asialo GM1 antibody suppression of cyclophosphamide-
induced diabetes in NOD mice. Diabetes Res 1991, 17:37-41.
[general reference]
173.Pearce RB, Peterson CM: Studies of concanavalin A in
nonobese diabetic mice. I. Prevention of insulin-dependent
diabetes. J Pharmacol Exp Ther 1991,  258:710-715 [general
reference]
Available online http://arthritis-research.com/content/4/S3/S003